Related Experiment Video
Updated: Jun 2, 2026
04:40
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
[Cancer and venous thromboembolism]
1Service de pneumologie-soins intensifs, hôpital Européen Georges-Pompidou, AP-HP, faculté de médecine, université Paris-Descartes, 20, rue Leblanc, 75015 Paris, France. guy.meyer@egp.aphp.fr
Revue Des Maladies Respiratoires
|May 10, 2011
Summary
Cancer patients frequently experience venous thromboembolism (VTE), a condition linked to poorer outcomes. Low-molecular weight heparin shows promise in reducing VTE incidence and potentially improving survival in cancer patients.
Area of Science:
- Oncology
- Hematology
- Thrombosis Research
Context:
- Cancer and venous thromboembolism (VTE) are closely linked, with VTE often indicating a worse prognosis for cancer patients.
- Tumor cells expressing procoagulants and treatments like chemotherapy contribute to increased thrombosis risk.
- VTE can be an initial sign of cancer, particularly within six months of idiopathic thrombosis.
Purpose:
- To summarize the current understanding of cancer-associated thrombosis.
- To review the role of low-molecular weight heparin (LMWH) in managing VTE in cancer patients.
- To highlight ongoing research into LMWH's potential direct anti-tumor effects and impact on long-term survival.
Summary:
- Venous thromboembolism (VTE) is a common and challenging complication in cancer patients.
- Current primary treatment for VTE in this population involves low-molecular weight heparin (LMWH) for 3-6 months.
- While LMWH shows potential for reducing VTE incidence and improving survival, further confirmation through large clinical trials is ongoing.
Impact:
- Low-molecular weight heparin (LMWH) may offer survival benefits beyond VTE treatment, potentially through direct anti-tumor effects.
- Ongoing clinical trials are crucial for validating LMWH's efficacy in improving long-term survival for cancer patients with VTE.
- Defining the role of long-term VTE prophylaxis in cancer patients remains an important area for future research.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...